Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study
- PMID: 22016816
- PMCID: PMC3189235
- DOI: 10.1371/journal.pone.0026091
Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study
Abstract
Background: Standard treatment for osteosarcoma patients consists of a combination of cisplatin, adriamycin, and methotrexate before surgical resection of the primary tumour, followed by postoperative chemotherapy including vincristine and cyclophosphamide. Unfortunately, many patients still relapse or suffer adverse events. We examined whether common germline polymorphisms in chemotherapeutic transporter and metabolic pathway genes of the drugs used in standard osteosarcoma treatment may predict treatment response.
Methodology/principal findings: In this study we screened 102 osteosarcoma patients for 346 Single Nucleotide Polymorphisms (SNPs) and 2 Copy Number Variants (CNVs) in 24 genes involved in the metabolism or transport of cisplatin, adriamycin, methotrexate, vincristine, and cyclophosphamide. We studied the association of the genotypes with tumour response and overall survival. We found that four SNPs in two ATP-binding cassette genes were significantly associated with overall survival: rs4148416 in ABCC3 (per-allele HR = 8.14, 95%CI = 2.73-20.2, p-value = 5.1×10⁻⁵), and three SNPs in ABCB1, rs4148737 (per-allele HR = 3.66, 95%CI = 1.85-6.11, p-value = 6.9×10⁻⁵), rs1128503 and rs10276036 (r² = 1, per-allele HR = 0.24, 95%CI = 0.11-0.47 p-value = 7.9×10⁻⁵). Associations with these SNPs remained statistically significant after correction for multiple testing (all corrected p-values [permutation test] ≤ 0.03).
Conclusions: Our findings suggest that these polymorphisms may affect osteosarcoma treatment efficacy. If these associations are independently validated, these variants could be used as genetic predictors of clinical outcome in the treatment of osteosarcoma, helping in the design of individualized therapy.
Conflict of interest statement
Figures
Similar articles
-
Effect of variation of ABCB1 and ABCC3 genotypes on the survival of bone tumor cases after chemotherapy.Asian Pac J Cancer Prev. 2013;14(8):4595-8. doi: 10.7314/apjcp.2013.14.8.4595. Asian Pac J Cancer Prev. 2013. PMID: 24083708
-
Predictive potential of ABCB1, ABCC3, and GSTP1 gene polymorphisms on osteosarcoma survival after chemotherapy.Tumour Biol. 2014 Oct;35(10):9897-904. doi: 10.1007/s13277-014-1917-x. Epub 2014 Jul 5. Tumour Biol. 2014. PMID: 24996541
-
Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma.Oncotarget. 2017 Feb 7;8(6):9388-9398. doi: 10.18632/oncotarget.11543. Oncotarget. 2017. PMID: 27566582 Free PMC article.
-
Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition.Curr Drug Targets. 2011 May;12(5):631-46. doi: 10.2174/138945011795378487. Curr Drug Targets. 2011. PMID: 21039333 Review.
-
Single nucleotide polymorphisms in ABCC2 and ABCB1 genes and their clinical impact in physiology and drug response.Cancer Lett. 2006 Mar 8;234(1):40-50. doi: 10.1016/j.canlet.2005.06.050. Epub 2005 Dec 27. Cancer Lett. 2006. PMID: 16377077 Review.
Cited by
-
Pharmacogenetics of chemotherapy treatment response and -toxicities in patients with osteosarcoma: a systematic review.BMC Cancer. 2022 Dec 19;22(1):1326. doi: 10.1186/s12885-022-10434-5. BMC Cancer. 2022. PMID: 36536332 Free PMC article.
-
Brazilian cohort and genes encoding for drug-metabolizing enzymes and drug transporters.Pharmacogenomics. 2020 Jun;21(9):575-586. doi: 10.2217/pgs-2020-0013. Epub 2020 Jun 3. Pharmacogenomics. 2020. PMID: 32486903 Free PMC article.
-
Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.Pharmacogenomics. 2014;15(12):1565-74. doi: 10.2217/pgs.14.107. Pharmacogenomics. 2014. PMID: 25340731 Free PMC article.
-
Association between GSTP1 polymorphisms and prognosis of osteosarcoma in patients treated with chemotherapy: a meta-analysis.Onco Targets Ther. 2015 Jul 23;8:1835-42. doi: 10.2147/OTT.S81115. eCollection 2015. Onco Targets Ther. 2015. PMID: 26229491 Free PMC article.
-
Impact of ABC Transporters in Osteosarcoma and Ewing's Sarcoma: Which Are Involved in Chemoresistance and Which Are Not?Cells. 2021 Sep 17;10(9):2461. doi: 10.3390/cells10092461. Cells. 2021. PMID: 34572110 Free PMC article. Review.
References
-
- Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 2006;6:1075–1085. - PubMed
-
- Redlich G, Zanger UM, Riedmaier S, Bache N, Giessing AB, et al. Distinction between human cytochrome P450 (CYP) isoforms and identification of new phosphorylation sites by mass spectrometry. J Proteome Res. 2008;7:4678–4688. - PubMed
-
- Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol. 1995;30:445–600. - PubMed
-
- Sissung TM, Gardner ER, Gao R, Figg WD. Pharmacogenetics of membrane transporters: a review of current approaches. Methods Mol Biol. 2008;448:41–62. - PubMed
-
- Kindla J, Fromm MF, Konig J. In vitro evidence for the role of OATP and OCT uptake transporters in drug-drug interactions. Expert Opin Drug Metab Toxicol. 2009;5:489–500. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases